Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang, China.
Can J Gastroenterol Hepatol. 2021 Jan 8;2021:8864655. doi: 10.1155/2021/8864655. eCollection 2021.
To explore the clinical characteristics of reactivation of hepatitis B virus (HBV) in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The pathological correlation of prognosis and hepatitis B virus reactivation has been given detailed analyses in our research.
A total of 108 related TACE-treated HCC clinical data from January 2008 to January 2016 was gleaned and involved in this retrospective analysis. To lucubrate the nuance of survival rates between HBV reactivated group and HBV nonreactivated group, clinical data of each patient was analyzed in detail and refined the retrospective studies.
HBV reactivation occurred in 42 patients with a proportion of 38.9%. The detected HBV DNA level ≥10 in patients showed a reactivation rate of 65.8% (25/38), which was significantly higher than the HBV DNA < 10 cases (24.3%, 17/70). Research data revealed a conspicuous lower cellular immunity ( < 0.01) and better 2-year survival rate (=0.03) in the HBV-reactivated group when compared to the nonreactivated group.
Some of the patients with primary hepatocellular carcinoma possibly had HBV reactivation at post-TACE-therapy. And the predominant risk factors of HBV reactivation are positive HBV test and immunosuppression. Our study suggested that HBV reactivation at post-TACE-therapy is an independent predictor of poor prognosis and low survival rate as well as a crucial reason for poor prognosis and lower survival rate, which indirectly proved that it is urgent to necessitate the antiviral therapy and immune enhancer in improving the curative effect and prognosis of HCC patients.
探讨经导管动脉化疗栓塞（TACE）后乙型肝炎病毒（HBV）再激活与肝细胞癌（HCC）的临床特征。本研究对预后与 HBV 再激活的病理相关性进行了详细分析。
回顾性分析 2008 年 1 月至 2016 年 1 月期间接受 TACE 治疗的 108 例相关 HCC 临床资料。为深入研究生存率在 HBV 再激活组与 HBV 未再激活组之间的细微差别，详细分析了每位患者的临床资料，并进行了回顾性研究细化。
42 例患者发生 HBV 再激活，占比 38.9%。HBV DNA 检测值≥10 的患者再激活率为 65.8%（25/38），明显高于 HBV DNA＜10 的患者（24.3%，17/70）。研究数据显示，与未再激活组相比，HBV 再激活组的细胞免疫明显较低（<0.01），2 年生存率较好（=0.03）。
部分原发性肝细胞癌患者在 TACE 治疗后可能发生 HBV 再激活。HBV 再激活的主要危险因素是 HBV 检测阳性和免疫抑制。本研究表明，TACE 后 HBV 再激活是预后不良和生存率低的独立预测因子，也是导致预后不良和生存率低的重要原因，这间接证明了抗病毒治疗和免疫增强剂在提高 HCC 患者疗效和预后方面的紧迫性。
